Should I buy or sell Immunome stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunome in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMNM shares. View IMNM analyst ratings or view top-rated stocks .

What is Immunome's stock price target for 2024?

6 Wall Street analysts have issued twelve-month price objectives for Immunome's stock. Their IMNM share price targets range from $30.00 to $35.00. On average, they predict the company's share price to reach $32.67 in the next twelve months. This suggests a possible upside of 73.3% from the stock's current price. View analysts price targets for IMNM or view top-rated stocks among Wall Street analysts .

How have IMNM shares performed in 2024?

Immunome's stock was trading at $10.70 at the beginning of the year. Since then, IMNM shares have increased by 76.2% and is now trading at $18.85. View the best growth stocks for 2024 here .

When is Immunome's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024. View our IMNM earnings forecast .

How were Immunome's earnings last quarter?

Immunome, Inc. (NASDAQ:IMNM) issued its earnings results on Monday, November, 15th. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.14. Immunome had a negative trailing twelve-month return on equity of 69.74% and a negative net margin of 761.92%.

What ETF holds Immunome's stock?

Invesco Dorsey Wright Healthcare Momentum ETF holds 66,447 shares of IMNM stock, representing 0.93% of its portfolio.

When did Immunome IPO?

Immunome (IMNM) raised $30 million in an initial public offering on Friday, October 2nd 2020. The company issued 2,500,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Chardan served as the underwriters for the IPO.

How do I buy shares of Immunome?

Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:IMNM

Immunome (IMNM) Stock Price, News & Analysis

→ Elon Musk’s ChatGPT Could Soon Mint New Millionaires (From InvestorPlace) (Ad)

Free IMNM Stock Alerts

$18.85

-1.73 (-8.41%)

(As of 04/15/2024 ET)

Compare

Today's Range: $18.83
▼
$21.72
50-Day Range: $18.85
▼
$27.34
52-Week Range: $4.44
▼
$30.96

Volume: 718,468 shs
Average Volume: 567,924 shs
Market Capitalization: $1.13 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $32.67

Get Immunome alerts:

Immunome MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 73.3% Upside
$32.67 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.20
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.91) to ($2.36) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.53 out of 5 stars

Medical Sector

715th out of 928 stocks

Pharmaceutical Preparations Industry

327th out of 428 stocks

3.5

Analyst's Opinion

Consensus Rating
Immunome has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Immunome has only been the subject of 4 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for IMNM.

0.0

Dividend Strength

Dividend Yield
Immunome does not currently pay a dividend.
Dividend Growth
Immunome does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IMNM.

2.9

News and Social Media Coverage

News Sentiment
Immunome has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Immunome this week, compared to 2 articles on an average week.
Search Interest
Only 4 people have searched for IMNM on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
MarketBeat Follows
Only 8 people have added Immunome to their MarketBeat watchlist in the last 30 days. This is a decrease of -53% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immunome insiders have not sold or bought any company stock.
Percentage Held by Insiders
20.00% of the stock of Immunome is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
44.58% of the stock of Immunome is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Immunome are expected to decrease in the coming year, from ($1.91) to ($2.36) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Immunome is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Immunome is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Immunome has a P/B Ratio of 6.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Forget Nvidia, buy this A.I. Stock Now

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

Click here to see the details.

About Immunome Stock (NASDAQ:IMNM)

Immunome, Inc. operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

IMNM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IMNM Stock News Headlines

April 16, 2024 | americanbankingnews.com

Immunome (NASDAQ:IMNM) Receives New Coverage from Analysts at Guggenheim

April 8, 2024 | americanbankingnews.com

Immunome, Inc. (NASDAQ:IMNM) to Post Q1 2024 Earnings of ($1.63) Per Share, Leerink Partnrs Forecasts

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

April 5, 2024 | businesswire.com

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

March 29, 2024 | investorplace.com

IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023

March 28, 2024 | markets.businessinsider.com

TD Cowen Reaffirms Their Buy Rating on Immunome (IMNM)

March 28, 2024 | businesswire.com

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

March 28, 2024 | businesswire.com

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

March 27, 2024 | finance.yahoo.com

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

March 22, 2024 | finance.yahoo.com

Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions

March 18, 2024 | msn.com

Arrayjet’s ArrayPlex platform selected by Immunome for use in its discovery of targeted cancer therapies

March 18, 2024 | businesswire.com

Arrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies

March 7, 2024 | businesswire.com

Immunome to Participate in the Leerink Partners Global Biopharma Conference

March 1, 2024 | businesswire.com

Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference

February 28, 2024 | msn.com

Biotech Stocks Surge To Start 2024: 'Charts Look Great,' But Will The Trend Continue?

February 24, 2024 | msn.com

Immunome (IMNM) Price Target Increased by 179.17% to 34.17

February 22, 2024 | benzinga.com

Immunome Stock (NASDAQ:IMNM), Short Interest Report

February 20, 2024 | finance.yahoo.com

Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

February 20, 2024 | businesswire.com

Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

February 19, 2024 | finance.yahoo.com

IMNM Apr 2024 30.000 call

February 19, 2024 | finance.yahoo.com

IMNM Mar 2024 10.000 put

February 17, 2024 | ca.finance.yahoo.com

IMNM Jul 2024 25.000 put

February 17, 2024 | ca.finance.yahoo.com

IMNM Mar 2024 20.000 put

February 17, 2024 | finance.yahoo.com

IMNM Apr 2024 12.500 put

February 17, 2024 | finance.yahoo.com

IMNM Apr 2024 7.500 call

February 17, 2024 | finance.yahoo.com

IMNM Mar 2024 22.500 put

See More Headlines

Receive IMNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/15/2024
Next Earnings (Estimated): 5/03/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:IMNM
CUSIP: N/A
CIK: 1472012
Web: immunome.com
Phone: 610-321-3700
Fax: N/A
Employees: 37
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $32.67
High Stock Price Target: $35.00
Low Stock Price Target: $30.00
Potential Upside/Downside: +73.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-106,810,000.00
Net Margins: -761.92%
Pretax Margin: -761.92%
Return on Equity: -69.74%
Return on Assets: -31.40%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.63
Quick Ratio: 6.63

Sales & Book Value

Annual Sales: $14.02 million
Price / Sales: 80.25
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.77 per share
Price / Book: 6.81

Miscellaneous

Outstanding Shares: 59,690,000
Free Float: 47,755,000
Market Cap: $1.13 billion
Optionable: Optionable
Beta: 1.66

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Clay B. Siegall Ph.D. (Age 63)
President, CEO & Chairman
Mr. Max Rosett (Age 34)
Interim CFO & Executive VP of Operations
Mr. Robert Lapetina (Age 49)
Principal Accounting Officer
Mr. Philip Roberts
Chief Technical Officer
Dr. Jack Higgins Ph.D. (Age 44)
Chief Scientific Officer
Ms. Sandra G. Stoneman Esq. (Age 51)
J.D., Chief Legal Officer, General Counsel & Corporate Secretary
Comp: $443.43k
Mr. Bruce Turner M.D. (Age 61)
Ph.D., Chief Strategy Officer
Dr. Robert J. Lechleider M.D.
Chief Medical Officer
Mr. Kinney Horn (Age 49)
Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IMNM Stock Analysis - Frequently Asked Questions

Should I buy or sell Immunome stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunome in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMNM shares.
View IMNM analyst ratings or view top-rated stocks.
What is Immunome's stock price target for 2024?: 6 Wall Street analysts have issued twelve-month price objectives for Immunome's stock. Their IMNM share price targets range from $30.00 to $35.00. On average, they predict the company's share price to reach $32.67 in the next twelve months. This suggests a possible upside of 73.3% from the stock's current price.
View analysts price targets for IMNM or view top-rated stocks among Wall Street analysts.
How have IMNM shares performed in 2024?: Immunome's stock was trading at $10.70 at the beginning of the year. Since then, IMNM shares have increased by 76.2% and is now trading at $18.85.
View the best growth stocks for 2024 here.
When is Immunome's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our IMNM earnings forecast.

How were Immunome's earnings last quarter?: Immunome, Inc. (NASDAQ:IMNM) issued its earnings results on Monday, November, 15th. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.14. Immunome had a negative trailing twelve-month return on equity of 69.74% and a negative net margin of 761.92%.
What ETF holds Immunome's stock?: Invesco Dorsey Wright Healthcare Momentum ETF holds 66,447 shares of IMNM stock, representing 0.93% of its portfolio.
When did Immunome IPO?: Immunome (IMNM) raised $30 million in an initial public offering on Friday, October 2nd 2020. The company issued 2,500,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Chardan served as the underwriters for the IPO.
How do I buy shares of Immunome?: Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMNM) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Immunome (IMNM) Stock Price, News & Analysis

Immunome MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Immunome Stock (NASDAQ:IMNM)

IMNM Stock Price History

IMNM Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

IMNM Stock Analysis - Frequently Asked Questions

Overall MarketRank^™